Diagnostics for Epidemic Preparedness- Devy Emperador, MPH

International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2018

PrEP On-Demand vs Conventional - Esper Kallas

Salvador HIV Clinical Forum 2022

Cost-utility analysis of dolutegravir- versus efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 96-week results from the NAMSAL ANRS 12313 trial

INTEREST 2020

Efficacy and Safety of the Once-Daily Darunavir /Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-Tablet Regimen in Antiretroviral Treatment (ART)-Experienced and ART-Naïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results

International Workshop on HIV & Women 2019

Mortality and Virologic Outcomes between Two to Five Years of Age after Early Initiation during Infancy of Antiretroviral Treatment: Experience of the ANRS-1240 Pediacam Study (Cameroon) - Francis Ateba Ndongo

INTEREST 2019

Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women - Michael Weber, PharmD

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Program Book - HIV Prevention Review Meeting 2021

Current and Future Local Therapies for Early Stage HCC -Shi-Ming Lin, MD

Tokyo Hepatitis Clinical Forum 2019

Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV co-infected patients with HCV GT1-4 Infection: The PHOTON-1 and -2 Trials|||| Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV and HIV-1 | Dr. J. Rockstroh

APACC 2016

Abstract Book | European Meeting on HIV & Hepatitis 2023